254 related articles for article (PubMed ID: 35182332)
1. A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions.
Del Regno L; Catapano S; Di Stefani A; Cappilli S; Peris K
Am J Clin Dermatol; 2022 May; 23(3):339-352. PubMed ID: 35182332
[TBL] [Abstract][Full Text] [Related]
2. Treatment considerations in actinic keratosis.
Goldenberg G
J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():12-16. PubMed ID: 28263018
[TBL] [Abstract][Full Text] [Related]
3. The importance of treating the field in actinic keratosis.
Stockfleth E
J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():8-11. PubMed ID: 28263021
[TBL] [Abstract][Full Text] [Related]
4. The paradigm shift in treating actinic keratosis: a comprehensive strategy.
Stockfleth E
J Drugs Dermatol; 2012 Dec; 11(12):1462-7. PubMed ID: 23377517
[TBL] [Abstract][Full Text] [Related]
5. Topical therapies for skin cancer and actinic keratosis.
Haque T; Rahman KM; Thurston DE; Hadgraft J; Lane ME
Eur J Pharm Sci; 2015 Sep; 77():279-89. PubMed ID: 26091570
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp.
Balcere A; Rone Kupfere M; Čēma I; Krūmiņa A
Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30987411
[TBL] [Abstract][Full Text] [Related]
7. Effect of ingenol mebutate on actinic keratosis in a Korean population: A prospective clinical, dermoscopic and histopathological study from a single center.
Kim JS; Woo YR; Kim M; Park HJ
J Dermatol; 2018 Nov; 45(11):1324-1330. PubMed ID: 30260493
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences for topical treatment of actinic keratoses: a discrete-choice experiment.
Kopasker D; Kwiatkowski A; Matin RN; Harwood CA; Ismail F; Lear JT; Thomson J; Hasan Z; Wali GN; Milligan A; Crawford L; Ahmed I; Duffy H; Proby CM; Allanson PF
Br J Dermatol; 2019 Apr; 180(4):902-909. PubMed ID: 29782648
[TBL] [Abstract][Full Text] [Related]
9. Safety of topical interventions for the treatment of actinic keratosis.
Koch EAT; Wessely A; Steeb T; Berking C; Heppt MV
Expert Opin Drug Saf; 2021 Jul; 20(7):801-814. PubMed ID: 33834933
[No Abstract] [Full Text] [Related]
10. Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies.
Kehrmann J; Koch F; Zumdick S; Höwner A; Best L; Masshöfer L; Scharfenberg S; Zeschnigk M; Becker JC; Schadendorf D; Buer J; Roesch A
Microbiol Spectr; 2023 Jun; 11(3):e0440122. PubMed ID: 37212689
[TBL] [Abstract][Full Text] [Related]
11. A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes.
Wood DLA; Lachner N; Tan JM; Tang S; Angel N; Laino A; Linedale R; Lê Cao KA; Morrison M; Frazer IH; Soyer HP; Hugenholtz P
mBio; 2018 Oct; 9(5):. PubMed ID: 30301852
[TBL] [Abstract][Full Text] [Related]
12. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications.
Feldman SR; Fleischer AB
Cutis; 2011 Apr; 87(4):201-7. PubMed ID: 21644496
[TBL] [Abstract][Full Text] [Related]
13. Intensity of Local Skin Reactions During 5-Fluorouracil Treatment Related to the Number of Actinic Keratosis Lesions: A Post Hoc, Exploratory Analysis.
Stockfleth E; Bégeault N; Delarue A
Dermatol Ther (Heidelb); 2022 Feb; 12(2):467-479. PubMed ID: 34954811
[TBL] [Abstract][Full Text] [Related]
14. In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis.
Ulrich M; Alarcon I; Malvehy J; Puig S
Dermatology; 2015; 230(3):193-8. PubMed ID: 25721522
[TBL] [Abstract][Full Text] [Related]
15. Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid.
Ulrich M; Pellacani G; Ferrandiz C; Lear JT
Eur J Dermatol; 2014; 24(2):158-67. PubMed ID: 24721544
[TBL] [Abstract][Full Text] [Related]
16. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
[TBL] [Abstract][Full Text] [Related]
17. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: Commonly used field-directed and lesion-directed therapies.
Berman B; Cohen DE; Amini S
Cutis; 2012 Jun; 89(6):294-301. PubMed ID: 22838095
[TBL] [Abstract][Full Text] [Related]
18. European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes).
Kandolf L; Peris K; Malvehy J; Mosterd K; Heppt MV; Fargnoli MC; Berking C; Arenberger P; Bylaite-Bučinskiene M; Del Marmol V; Dirschka T; Dreno B; Forsea AM; Harwood CA; Hauschild A; Heerfordt IM; Kauffman R; Kelleners-Smeets N; Lallas A; Lebbe C; Leiter U; Longo C; Mijušković Ž; Pellacani G; Puig S; Saiag P; Šitum M; Stockfleth E; Salavastru C; Stratigos A; Zalaudek I; Garbe C;
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):1024-1047. PubMed ID: 38451047
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.
Puviani M; Galloni C; Marchetti S; Sergio Pavone P; Lovati S; Pistone G; Caputo V; Tilotta G; Scarcella G; Campione E; Diluvio L; Garofalo V; Bianchi L; Milani M
Curr Med Res Opin; 2017 Jul; 33(7):1255-1259. PubMed ID: 28358282
[TBL] [Abstract][Full Text] [Related]
20. Topical management of actinic keratosis and field cancerisation.
Stockfleth E
G Ital Dermatol Venereol; 2009 Aug; 144(4):459-62. PubMed ID: 19755950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
